^
    Back
    Association details:
    Biomarker:GATA3 mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:milademetan (RAIN-32) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

    Excerpt:
    ...Molecular screening step -patients with unknown GATA3 mutational status will be identified either locally or centrally (Institut Curie core Genetics facility) after consenting for this molecular screening....
    Trial ID:
    DEMETER
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SABCS 2022
    Title:

    P6-10-10 Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

    Published date:
    11/22/2022
    Excerpt:
    Preclinical data show that the MDM2 inhibitor milademetan has antitumor activity in GATA3-mutant and MDM2-amplified HR+ breast cancers, and support the clinical evaluation of milademetan in these tumors.